3
|
Wong SL, Leung FP, Lau CW, Au CL, Yung LM, Yao X, Chen ZY, Vanhoutte PM, Gollasch M, Huang Y. Cyclooxygenase-2–Derived Prostaglandin F
2α
Mediates Endothelium-Dependent Contractions in the Aortae of Hamsters With Increased Impact During Aging. Circ Res 2009; 104:228-35. [DOI: 10.1161/circresaha.108.179770] [Citation(s) in RCA: 135] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Hypertension and vascular dysfunction result in the increased release of endothelium-derived contracting factors (EDCFs), whose identity is poorly defined. We tested the hypothesis that endothelial cyclooxygenase (COX)-2 can generate EDCFs and identified the possible EDCF candidate. Changes in isometric tension of aortae of young and aged hamsters were recorded on myograph. Real-time changes in intracellular calcium concentrations ([Ca
2+
]
i
) in native aortic endothelial cells were measured by imaging. Endothelium-dependent contractions were triggered by acetylcholine (ACh) after inhibition of nitric oxide production and they were abolished by COX-2 but not COX-1 inhibitors or by thromboxane–prostanoid receptor antagonists. 2-Aminoethoxydiphenyl borate (cation channel blocker) eliminated endothelium-dependent contractions and ACh-stimulated rises in endothelial cell [Ca
2+
]
i
. RT-PCR and Western blotting showed COX-2 expression mainly in the endothelium. Enzyme immunoassay and high-performance liquid chromatography-coupled mass spectrometry showed release of prostaglandin (PG)F
2α
and prostacyclin (PGI
2
) increased by ACh; only PGF
2α
caused contraction at relevant concentrations. COX-2 expression, ACh-stimulated contractions, and vascular sensitivity to PGF
2α
were augmented in aortae from aged hamsters. Human renal arteries also showed thromboxane–prostanoid receptor–mediated ACh- or PGF
2α
-induced contractions and COX-2–dependent release of PGF
2α
. The present study demonstrates that PGF
2α
, derived from COX-2, which is localized primarily in the endothelium, is the most likely EDCF underlying endothelium-dependent, thromboxane–prostanoid receptor–mediated contractions to ACh in hamster aortae. These contractions involved increases in endothelial cell [Ca
2+
]
i
. The results support a critical role of COX-2 in endothelium-dependent contractions in this species with an increased importance during aging and, possibly, a similar relevance in humans.
Collapse
Affiliation(s)
- Siu Ling Wong
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Fung Ping Leung
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Chi Wai Lau
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Chak Leung Au
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Lai Ming Yung
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Xiaoqiang Yao
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Zhen-Yu Chen
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Paul M. Vanhoutte
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Maik Gollasch
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| | - Yu Huang
- From the Institute of Vascular Medicine (S.L.W., F.P.L., X.Y., Z.-Y.C., Y.H.) and Departments of Physiology (S.L.W., F.P.L., C.W.L., C.L.A., L.M.Y., X.Y., Y.H.) and Biochemistry (Z.-Y.C.), Chinese University of Hong Kong, China; Department of Pharmacology (P.M.V.), University of Hong Kong, China; and Medical Clinic for Nephrology and Internal Intensive Care (M.G.), Charité University Medicine Berlin, Germany
| |
Collapse
|
5
|
Fumagalli F, Rossoni M, Iriti M, di Gennaro A, Faoro F, Borroni E, Borgo M, Scienza A, Sala A, Folco G. From field to health: a simple way to increase the nutraceutical content of grape as shown by NO-dependent vascular relaxation. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2006; 54:5344-9. [PMID: 16848515 DOI: 10.1021/jf0607157] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Polyphenolic grapevine components involved in plant resistance against pathogens possess various pharmacological properties that include nitric oxide (NO)-dependent vasodilation and anti-inflammatory and free radical scavenging activities, which may explain the protective effect of moderate red wine consumption against cardiovascular disease. The aim of this work was (a) to verify the possibility that preharvest treatments of grapevine with a plant activator, benzo-(1,2,3)-thiadiazole-7-carbothioic acid S-methyl ester (BTH), could lead to an enriched nutraceutical potential of wine and (b) to characterize the profile of metabolites responsible for pharmacological activity. Plant spraying at the end of veraison, with a water suspension of BTH (0.3 mM), led to increased whole anthocyanin content as confirmed by HPLC comparative analysis. Extracts from berry skins of BTH-treated grapevines caused NO-dependent vasorelaxation, with a concentration-response curve that was significantly shifted to the left of the control non-BTH-treated curve. Moreover, 1:1000 dilutions of berry extracts from BTH-treated plants significantly increased basal production of guanosine 3',5'-cyclic monophosphate (cGMP) in human vascular endothelial cells when compared to the corresponding extracts of untreated plants. These results show that BTH treatment increases anthocyanin content of grape extracts, as well as their ability to induce NO-mediated vasoprotection. No increase of anthocyanin content was observed in the wine extracts from BTH-treated vines. It is concluded that BTH treatment could be exploited to increase the nutraceutical potential of grapes.
Collapse
Affiliation(s)
- Francesca Fumagalli
- Dipartimento di Scienze Farmacologiche, and Istituto di Patologia Vegetale, Università di Milano, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Buccellati C, Sala A, Rossoni G, Capra V, Rovati GE, Di Gennaro A, Folco G, Colli S, Casagrande C. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations. J Pharmacol Exp Ther 2006; 317:830-7. [PMID: 16399881 DOI: 10.1124/jpet.105.097170] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Thromboxane (TX) A(2), prostacyclin (PGI(2)), and nitric oxide (NO) regulate platelet function and interaction with the vessel wall. Inhibition of TXA(2), implemented synthesis of PGI(2), and supply of exogenous NO may afford therapeutic benefit. 2NTX-99 [4-methoxy-N(1)-(4-trans-nitrooxycyclohexyl)-N(3)-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a new chemical entity related to picotamide, showed antithromboxane activity and NO donor properties. 2NTX-99 relaxed rabbit aortic rings precontracted with norepinephrine or U46619 (9,11-dideoxy-9alpha,11alpha-methanoepoxy-prosta-5Z,13E-dien-1-oic acid; EC(50), 7.9 and 17.1 microM, respectively), an effect abolished by 10 microM 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ). 2NTX-99 inhibited arachidonic acid (AA)-induced washed platelet aggregation (EC(50), 9.8 microM) and TXB(2) formation (-71% at 10 microM), and its potency increased in the presence of aortic rings (EC(50), 1.4 microM). In whole rabbit aorta incubated with homologous platelets, AA caused contraction and TXA(2) formation, reduced by 2NTX-99 (10-40 microM): contraction, -28 and -47%, TXA(2) formation, -37 and -75.4%, respectively, with concomitant increase in PGI(2). 2NTX-99 (20-40 microM) inhibited U46619-induced aggregation in rabbit platelet-rich plasma (PRP) (-74 +/- 6.7 and -96 +/- 2.4%, respectively) and inhibited collagen-induced aggregation in human PRP (-48.2 +/- 10 and -79.2 +/- 6%), whereas ozagrel was ineffective. In human embryonic kidney 293 cells transfected with the TXA(2) receptor isophorm alpha receptor, 2NTX-99 did not compete with the ligand, [(3)H]SQ29,548 ([(3)H][1S-[1alpha,2beta(5Z),3beta,4alpha]]-7-[3-[[2-(phenylamino)-carbonyl]hydrazino]methyl]-7-oxabicyclo[2,2,1]-hept-2-yl]-5-heptanoic acid), or prevent inositol phosphate accumulation. After oral administration (50-250 mg/kg), 2NTX-99 inhibited TXA(2) production in rat clotting blood (-71 and -91%); at 250 mg/kg, an area under the curve, 0 to 16 h, of 149.5 h/microg/ml and a t(1/2) of 6 h were calculated, with a C(max) value of 31.8 +/- 8.2 microg/ml. An excellent correlation between plasma concentrations and TXA(2) inhibition occurs. 2NTX-99 controls platelet function and vessel wall interaction by multifactorial mechanisms and possesses therapeutic potential.
Collapse
Affiliation(s)
- Carola Buccellati
- Department of Pharmacological Sciences, School of Pharmacy, 20133 Milano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Guerrero JA, Lozano ML, Castillo J, Benavente-García O, Vicente V, Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 2005; 3:369-76. [PMID: 15670046 DOI: 10.1111/j.1538-7836.2004.01099.x] [Citation(s) in RCA: 129] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Dietary flavonoids are known for their antiplatelet activity resulting in cardiovascular protection, although the specific mechanisms by which this inhibition occurs has not been fully established. OBJECTIVE The aim of this study was to investigate the interaction of nine flavonoids representative of various chemical classes, with platelet responses dependent on thromboxane A(2) (TxA(2)) generation and on receptor antagonism, and to analyze the structural requirements for such effects. METHODS The effect of several types of flavonoids on platelet aggregation, serotonin release, and TxA(2) generation was investigated. Competitive radioligand binding assays were used to screen for affinity of these compounds to TxA(2) receptors. RESULTS Flavones (apigenin and luteolin) and isoflavones (genistein) abrogated arachidonic acid and collagen-induced platelet responses, such as aggregation and secretion, with a less substantial effect on TxA(2) synthesis. These compounds were identified as specific ligands of the TxA(2) receptor in the micromol L(-1) range, this effect accounting for antiplatelet effects related to stimulation with those agonists. Tight binding of flavonoids to the human TxA(2) receptor relies on structural features such as the presence of the double bond in C2-C3, and a keto group in C4. CONCLUSIONS The inhibition by specific flavonoids of in vitro platelet responses induced by collagen or arachidonic acid seems to be related, to a great extent, to their ability to compete for binding to the TxA(2) receptor. Therefore, antagonism of this TxA(2) receptor may represent an additional mechanism for the inhibitory effect of these compounds in platelet function.
Collapse
Affiliation(s)
- J A Guerrero
- Unit of Hematology and Clinical Oncology, Centro Regional de Hemodonación, Spain
| | | | | | | | | | | |
Collapse
|